This article is more than 5 years old. Information may no longer be current.
First patient gets neural stem cell transplant in phase 1/2 dry AMD trial
The first transplant has been completed in StemCells Inc.’s phase 1/2 clinical trial to study the safety and efficacy of its proprietary purified human neural stem cell product candidate as a treatment for dry age-related macular degeneration, according to a press release.
The stem cell transplant took place Oct. 3 at the Retina Foundation of the Southwest in Dallas.
The phase 1/2 trial is expected to enroll 16 patients in an open-label, dose-escalation study during which the cells will be administered by a single injection into the space beneath the retina in the most affected eye, the release said. Subjects will be evaluated at sets times for 1 year after administration to assess safety and signs of visual benefit. They will then be followed in a separate observational study for 4 more years.